



an Open Access Journal by MDPI

Gut Microbial Dysbiosis in Disease Pathogenesis

Guest Editors:

Dr. Pugazhendhi Srinivasan
School of Medicine, University of
Kansas Medical Center, Kansas
City, KS, USA

**Dr. Nanda Kumar Navalpur
Shanmugam**
Department of Neurology,
Massachusetts General Hospital
and Harvard Medical School,
Charlestown, MA 02129, USA

Deadline for manuscript
submissions:
closed (31 January 2024)

Message from the Guest Editors

Dear Colleagues,

Gut microbiota is considered an organ of the human system due to multiple functional roles. This is an adaptive and dynamic system that reflects the health status and can be a potential biomarker in the future. Microbiota plays important roles in training the immune system and various metabolic pathways.

The role of microbial dysbiosis in causing diseases is clear from the increase in allergic and autoimmune diseases observed in developing countries as seen in developed countries. This is attributed to changes in the diet and lifestyle that are considered to affect the microbiota.

With affordable next-generation sequencing, microbiome studies are conducted at small and large scales to explore various human diseases. These studies mostly profile dysbiosis. Microbiome studies in the future are required to establish the mechanistic role of microbial dysbiosis in various disease pathogenesises.

This Special Issue invites original research and review articles that expand our knowledge on the role of dysbiosis in disease pathogenesis. Studies conducted in animal models and human subjects will be accepted for submission.



mdpi.com/si/145096

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)